If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. ...

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: McKesson (MCK) reported $96.3 billion in revenue for the quarter ended March 2026, representing a year- over-year increase of 6%. EPS of $11.69 for the same period compares to $10.12 a year ago. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics alw ...

McKesson (MCK) came out with quarterly earnings of $11.69 per share, beating the Zacks Consensus Estimate of $11.56 per share. This compares to earnings of $10.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.14%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $9.31 per share when it actually produced earnings of $9.34, delivering a surprise of +0.32%.Over the last four quart ...

公司业绩与财务指引 - 公司发布2027财年利润指引 略高于华尔街预期 [1] - 公司2025财年第一季度利润超出市场预期 [1] 业务表现与驱动因素 - 美国药品分销业务表现强劲 特别是在肿瘤学和专科药领域 [1]

McKesson (NYSE:MCK) Q4 2026 Earnings call May 07, 2026 04:30 PM ET Company ParticipantsBrian Tyler - CEOBritt Vitalone - CFOElizabeth Anderson - Senior Managing DirectorGlen Santangelo - Managing DirectorJeni Dominguez - VP of Investor RelationsLisa Gill - Managing DirectorConference Call ParticipantsAllen Lutz - Senior Equity Research AnalystBrian Tanquilut - Senior Equity Research AnalystCharles Rhyee - Senior Equity Research AnalystDaniel Grosslight - Senior Research AnalystErin Wright - Equity AnalystMi ...

McKesson (NYSE:MCK) Q4 2026 Earnings call May 07, 2026 04:30 PM ET Company Participants Brian Tyler - CEO Britt Vitalone - CFO Elizabeth Anderson - Senior Managing Director Glen Santangelo - Managing Director Jeni Dominguez - VP of Investor Relations Lisa Gill - Managing Director Conference Call Participants Allen Lutz - Senior Equity Research Analyst Brian Tanquilut - Senior Equity Research Analyst Charles Rhyee - Senior Equity Research Analyst Daniel Grosslight - Senior Research Analyst Erin Wright - Equi ...

McKesson (NYSE:MCK) Q4 2026 Earnings call May 07, 2026 04:30 PM ET Speaker12Welcome to McKesson's fourth quarter fiscal 2026 earnings conference call. Please be advised that today's conference is being recorded. At this time, I would like to turn the conference over to Jeni Dominguez, VP of Investor Relations. Please go ahead.Speaker9Thank you, operator. Good afternoon, and welcome everyone to McKesson's fourth quarter fiscal 2026 earnings call. Today I'm joined by Brian Tyler, our Chief Executive Officer, ...

业绩总结 - 麦克森公司第四季度的季度收入为963亿美元，同比增长6%[13] - 第四季度调整后每股收益为11.69美元，同比增长16%[14] - 2026财年总收入为4034.3亿美元，同比增长12%[18] - 2026财年调整后净收入为48.53亿美元，同比增长15%[18] 用户数据 - 第四季度北美制药部门收入为791.2亿美元，同比增长3%[22] - 第四季度肿瘤与多专科部门收入为127.11亿美元，同比增长35%[23] - 第四季度处方技术解决方案收入为14.95亿美元，同比增长12%[24] - 第四季度医疗外科解决方案收入为28.68亿美元，同比增长1%[26] 未来展望 - 2027财年调整后每股收益指导范围为43.80至44.60美元，预计同比增长12%至14%[33] - 2027财年收入预计增长5%至9%[39] - 2027财年运营利润预计增长8%至12%[39] - 2027财年自由现金流预计为45亿至49亿美元[39] 新产品和新技术研发 - 2026年第一季度的运营利润为2,186百万美元，较2025年的1,560百万美元增长40%[62] 市场扩张和并购 - 2026年3月31日止年度的肿瘤与多专科业务中，交易和整合费用的税前费用为9600万美元，涉及对PRISM Vision Holdings, LLC和Core Ventures的收购[71] 负面信息 - 2025年3月31日止年度的索赔和诉讼费用中，税前费用为1.14亿美元，涉及与全国性第三方支付者的阿片类药物索赔相关[72] - 2025年3月31日止年度的其他调整中，税前费用为8700万美元，涉及与英国冻结的养老金计划的和解费用相关[72]

Exhibit 99.1 McKESSON REPORTS FISCAL 2026 FOURTH QUARTER AND FULL YEAR RESULTS, PROVIDES FISCAL 2027 GUIDANCE, AND REAFFIRMS LONG-TERM FINANCIAL GROWTH TARGETS IRVING, Texas, May 7, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2026. Fourth Quarter Highlights: Full Year Highlights: Outlook: "McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our ...